Imperial is participating in JISC’s Read and Publish agreement with Elsevier from January 2022 until end of December 2024.

The agreement provides Open Access publishing for Corresponding Authors in Core Hybrid, Cell Press and The Lancet titles and read access to existing ScienceDirect and Cell Press Journals at no further charge to the author. It also provides a 15% discount on OA publishing in Elsevier's portfolio of fully open access titles.

 To be eligible, articles must:

  • Be in a participating journal (Note that fully gold journals with a 15% discount will not show in the journal search tool)
  • Be a research or review article. This includes Case Reports / Data in Brief / Microarticle / Original Software Publication / Protocol / Replication Study / Short Communication / Short Survey / Video Article / Practice Guideline. Some exceptions apply for Cell Press and The Lancet publications
  • Be accepted for publication between 1 January 2022 and 31 December 2024
  • Have a corresponding author affiliated with an eligible institution

Once your article has been accepted for publication in a participating journal, you will receive an email containing a link to the “post-acceptance author journey”. Upon selecting your publishing options, your affiliation will be validated by your institution, and you will be informed if the APC will be covered by the agreement or receive a 15% discount (if a Gold OA journal).

If the institution does not validate paying the APC, then the author receives an invoice for the full APC. In case an author has no funding available, they should contact Elsevier via their email form to change the publishing option to subscription to publish free of charge within two weeks of Elsevier sending the invoice.

 Full instructions are available on the Elsevier open access agreement for Jisc institutions webpage.

 If you have any questions regarding this agreement or the process please contact the open access team.